Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nebulized IVX-0142 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Nebulized IVX-0142 | DRUG | - |
Inclusion Criteria: * Mild stable allergic asthma * Positive skin-prick test to at least one common aeroallergen * Positive methacholine challenge * Positive allergen-induced early- and late-phase airway bronchoconstriction * General good health Exclusion Criteria: * Lung diseases other than mild...
IVX-0142 is an investigational small molecule being developed for the treatment of asthma. It is administered via nebulization and is intended for patients with mild allergic asthma. The drug is currently in Phase 2 clinical development and is not yet approved for use.
IVX-0142 is being developed by Teva Pharmaceutical Industries Limited, a company traded on the New York Stock Exchange under the ticker symbol TEVA. The drug is currently in Phase 2 clinical trials for the treatment of asthma.
IVX-0142 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 2 study of the drug has been completed, but it remains in clinical development.
IVX-0142 has one completed Phase 2 clinical trial registered as NCT00232999. This study evaluated the efficacy and safety of nebulized IVX-0142 in patients with mild allergic asthma. The trial enrolled 15 participants and was conducted in Canada.
No alternative names for IVX-0142 have been reported. The drug is identified by its code name IVX-0142 and is being developed by Teva Pharmaceutical Industries Limited for the treatment of asthma.